The funding was provided by o2h Ventures to back the University of Sussex spin out.
"We are delighted to be working with the University of Sussex and the founders to launch and grow Stingray Bio. We have been following the science for several years and we are now excited to support the commercialisation of the founder's research to develop new drugs for cancer."
The health technology company has closed a £8.7m Series B investment backed by high-profile angel investors.
"Low-cost, non-invasive technology for monitoring blood to a high standard is a holy grail that has profound, life-enhancing impact – whether you are monitoring metabolic health to improve athletic performance, or working to reverse the trend towards diabetes. I’m delighted to be working on developing such transformative products based on Zedsen’s novel non-invasive technology and being part of Zedsen’s amazing team."
Calm/Storm VC led the pre-seed round, which also saw participation from QVentures and an innovation grant from InnovateUK.
"Our mission at Béa is to democratise access to effective fertility treatments; providing people with more options. ICI is clinically proven to be highly effective when it comes to increasing the chances of conception, but it’s not made available to people at the beginning of their fertility journey. Instead, they have to take a big leap into the expensive world of invasive treatments. But for people where there’s no medically-identified issue causing infertility, ICI can be the ideal way of maximising their chances of getting pregnant. We’re designing a product that enables people to do this easily and affordably, all from home."
The Series A round featured participation from Sonoma Brands, Waldencast, Felix Capital, and Cherry Ventures.
"We’ve been encouraged to see men of all ages increasingly turning to Manual to solve multiple health problems, with almost half of our customers seeking help for more than one issue. It’s clear that a health concern may have more than one cause, and we can provide customers with the ability to treat their health in a more holistic way. Using different treatments to understand and improve their wellbeing."
The digital health company raised the capital to scale its AI powered patient management platform and support remote care programmes.
"Greater Manchester is the only place in the UK that can provide us the data partnerships, research support, diverse population and integrated health and social care practices that will enable us to give healthcare professionals the control and trust in the unbiased intelligence that powers our patient management system."